Beijing SL Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 8.77%

Beijing SL Pharmaceutical Co Ltd (002038) has an Asset Resilience Ratio of 8.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing SL Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥512.01 Million
≈ $74.92 Million USD Cash + Short-term Investments

Total Assets

CN¥5.84 Billion
≈ $854.10 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2003–2025)

This chart shows how Beijing SL Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Beijing SL Pharmaceutical Co Ltd (002038) total assets.

Liquid Assets Composition Over Time

This chart breaks down Beijing SL Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Beijing SL Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥512.01 Million 8.77%
Total Liquid Assets CN¥512.01 Million 8.77%

Asset Resilience Insights

  • Limited Liquidity: Beijing SL Pharmaceutical Co Ltd maintains only 8.77% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Beijing SL Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing SL Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Beijing SL Pharmaceutical Co Ltd (2003–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing SL Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 8.22% CN¥498.95 Million
≈ $73.01 Million
CN¥6.07 Billion
≈ $888.54 Million
+0.17pp
2024-12-31 8.04% CN¥480.86 Million
≈ $70.36 Million
CN¥5.98 Billion
≈ $874.92 Million
-15.04pp
2023-12-31 23.08% CN¥1.45 Billion
≈ $212.06 Million
CN¥6.28 Billion
≈ $918.63 Million
+8.48pp
2022-12-31 14.61% CN¥858.27 Million
≈ $125.59 Million
CN¥5.88 Billion
≈ $859.82 Million
+11.79pp
2021-12-31 2.82% CN¥162.36 Million
≈ $23.76 Million
CN¥5.76 Billion
≈ $842.94 Million
-0.40pp
2020-12-31 3.22% CN¥173.81 Million
≈ $25.43 Million
CN¥5.39 Billion
≈ $789.43 Million
+0.53pp
2019-12-31 2.69% CN¥140.45 Million
≈ $20.55 Million
CN¥5.22 Billion
≈ $764.58 Million
+2.09pp
2018-12-31 0.59% CN¥29.65 Million
≈ $4.34 Million
CN¥4.99 Billion
≈ $729.94 Million
-0.94pp
2017-12-31 1.53% CN¥70.31 Million
≈ $10.29 Million
CN¥4.59 Billion
≈ $670.94 Million
+0.64pp
2016-12-31 0.89% CN¥36.48 Million
≈ $5.34 Million
CN¥4.08 Billion
≈ $597.22 Million
-0.14pp
2015-12-31 1.03% CN¥38.73 Million
≈ $5.67 Million
CN¥3.76 Billion
≈ $550.44 Million
+0.74pp
2014-12-31 0.29% CN¥9.47 Million
≈ $1.39 Million
CN¥3.32 Billion
≈ $485.68 Million
+0.05pp
2013-12-31 0.23% CN¥6.35 Million
≈ $929.58K
CN¥2.71 Billion
≈ $396.87 Million
-0.17pp
2012-12-31 0.40% CN¥8.91 Million
≈ $1.30 Million
CN¥2.22 Billion
≈ $324.37 Million
-0.10pp
2011-12-31 0.51% CN¥8.78 Million
≈ $1.29 Million
CN¥1.74 Billion
≈ $254.05 Million
-0.42pp
2010-12-31 0.93% CN¥11.57 Million
≈ $1.69 Million
CN¥1.25 Billion
≈ $182.71 Million
-1.22pp
2009-12-31 2.14% CN¥21.86 Million
≈ $3.20 Million
CN¥1.02 Billion
≈ $149.23 Million
+0.59pp
2008-12-31 1.55% CN¥12.22 Million
≈ $1.79 Million
CN¥788.52 Million
≈ $115.38 Million
-3.74pp
2007-12-31 5.29% CN¥31.05 Million
≈ $4.54 Million
CN¥586.63 Million
≈ $85.84 Million
+1.66pp
2005-12-31 3.64% CN¥14.76 Million
≈ $2.16 Million
CN¥405.91 Million
≈ $59.40 Million
-5.59pp
2003-12-31 9.22% CN¥14.00 Million
≈ $2.05 Million
CN¥151.83 Million
≈ $22.22 Million
--
pp = percentage points

About Beijing SL Pharmaceutical Co Ltd

SHE:002038 China Drug Manufacturers - Specialty & Generic
Market Cap
$844.87 Million
CN¥5.77 Billion CNY
Market Cap Rank
#9724 Global
#2514 in China
Share Price
CN¥5.62
Change (1 day)
+0.36%
52-Week Range
CN¥5.03 - CN¥8.98
All Time High
CN¥10151.79
About

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more